Advertisement

Organisation › Details
Horizon Discovery Ltd.
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company's proprietary technology, GENESIS, is the world's most precise genome editing technology. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Horizon has harnessed GENESIS to create over 400 X-MAN cell lines, the world's first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These 'patients-in-a-test-tube' are being used by academic and industry leaders to identify the effect of individual genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the 'right drugs' for the 'right patients' based upon the unique genetic mutations that define their disease. In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms. *
![]() |
Start | 2007-06-01 established |
Group | PerkinElmer (Group) | |
![]() |
Industry | drug discovery |
![]() |
Person | Disley, Darrin M. (Mogrify 201902– CEO of Cell Mogrify Ltd before 11 years at Horizon Discovery) |
Person 2 | Vellacott, Richard (Horizon Discovery 201207– CFO before VP Finance at CSR plc before Deloitte) | |
![]() |
Region | Waterbeach, Cambridgeshire |
Country | United Kingdom (GB) | |
Street | Building 7300 IQ Cambridge | |
City | CB25 9TL Waterbeach, Cambridgeshire | |
Tel | +44-1223-655580 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement

More documents for PerkinElmer (Group)
- [1] SparingVision SAS. (3/3/25). "Press Release: SparingVision Appoints Anjeza Gjino as Chief Financial Officer". Paris....
- [2] CN Bio Innovations Ltd.. (3/14/23). "Press Release: CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing". Cambridge....
- [3] CN Bio Innovations Ltd.. (12/19/22). "Press Release: CN Bio Appoints Dr Paul Brooks as Chief Executive Officer". Cambridge....
- [4] PerkinElmer, Inc.. (6/22/21). "Press Release: PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader Sirion Biotech". Waltham, MA....
- [5] PerkinElmer, Inc.. (5/17/21). "Press Release: PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC". Waltham, MA....
- [6] PerkinElmer, Inc.. (5/12/21). "Press Release: PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience". Waltham, MA....
- [7] Congenica Ltd.. (4/6/21). "Press Release: Congenica Appoints Jayesh Pankhania as Chief Financial Officer". Cambridge....
- [8] Sirion Biotech GmbH. (1/7/21). "Press Release: Sirion Biotech GmbH Licensed Its LentiBoost Transduction Technology to Cellectis". Munich & Cambridge, MA....
- [9] PerkinElmer, Inc.. (1/7/21). "Press Release: PerkinElmer to Acquire Oxford Immunotec Global plc". Waltham, MA & London....
- [10] PerkinElmer, Inc.. (11/2/20). "Press Release: PerkinElmer to Acquire Cell Engineering Company Horizon Discovery for $383 Million (£296 Million)". Waltham, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top